

Appl. No. 10/699,351
Atty. Docket No. 9129L
Amdt. dated January 5, 2007
Reply to Office Action of July 5, 2006
Customer No. 27752

RECEIVED
CENTRAL FAX CENTER
JAN 05 2007

CLAIM LISTING

This listing of claims replaces all prior versions, and listings, of Claims in the application:

Listing of Claims

1. (Original) A composition comprising:
 - (a) a stiffening agent having a complete melting point of about 33 °C or greater which is selected from the group consisting of R-COOR', R-OR', R-CONR'R", R-NR'R", salts thereof, and mixtures thereof, wherein:
 - (i) R is selected from the group consisting of alkyl radicals having from about 14 to about 24 carbon atoms, alkenyl radicals having from about 14 to about 24 carbon atoms, alkynyl radicals having from about 14 to about 24 carbon atoms, heteroalkyl radicals having from about 14 to about 24 carbon atoms, heteroalkenyl radicals having from about 14 to about 24 carbon atoms, and heteroalkynyl radicals having from about 14 to about 24 carbon atoms; and
 - (ii) R' and R" are each, independently, selected from the group consisting of hydrogen, alkyl radicals, alkenyl radicals, alkynyl radicals, heteroalkyl radicals, heteroalkenyl radicals, and heteroalkynyl radicals; and
 - (b) a lipase inhibitor;wherein the ratio of the stiffening agent to the lipase inhibitor, by weight, is at least about 4.5 : 1.
2. (Original) The composition according to Claim 1 wherein the ratio of the stiffening agent to the lipase inhibitor, by weight, is at least about 5 : 1.
3. (Original) The composition according to Claim 2 wherein the stiffening agent is selected from the group consisting of fatty acids, salts of fatty acids, and mixtures thereof.

Appl. No. 10/699,351
Atty. Docket No. 9129L
Amdt. dated January 5, 2007
Reply to Office Action of July 5, 2006
Customer No. 27752

4. (Original) The composition according to Claim 3 wherein when the composition comprises a fatty acid, the composition further comprises a pharmaceutically-acceptable salt.
5. (Original) The composition according to Claim 3 wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatins; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.
6. (Original) The composition according to Claim 5 wherein the lipase inhibitor is a compound selected from the group consisting of tetrahydrolipstatin, lipstatin, and mixtures thereof.
7. (Original) The composition according to Claim 6 comprising at least about 0.001% of the lipase inhibitor and at least about 0.1% of the stiffening agent, all by weight of the composition.
8. (Original) The composition according to Claim 7 wherein the ratio of the stiffening agent to the lipase inhibitor, by weight, is at least about 6 : 1.
9. (Original) The composition according to Claim 8 comprising at least about 0.2% of the stiffening agent, by weight of the composition.
10. (Original) The composition according to Claim 9 comprising at least about 0.8% of the stiffening agent, by weight of the composition.
11. (Original) The composition according to Claim 10 wherein the lipase inhibitor is tetrahydrolipstatin.
12. (Original) The composition according to Claim 10 wherein the stiffening agent is selected from the group consisting of calcium stearate, behenic acid, and mixtures thereof.